Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Solid Tumors 2Thrombocythemia, Essential 1Rhabdoid Tumor 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Central Nervous System Neoplasms 1

Interventions

ruxolitinib 5Filgrastim 4Decitabine 4Cyclophosphamide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Etoposide 3Topotecan 2Tacrolimus 2Prednisone 2LY2784544 2Cytarabine 2Cyclosporine 2Carboplatin 2Antilymphocyte Serum 2veliparib 1tipifarnib 1talazoparib 1spartalizumab 1sonidegib 1sargramostim 1sabatolimab 1romidepsin 1pyroxamide 1poly ICLC 1peginterferon alfa-2a 1nelarabine 1navitoclax 1arsenous acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Thrombocythemia, Essential × RG7388 × Clear all
NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡